Swedbank AB Purchases 329,794 Shares of BioMarin Pharmaceutical Inc. $BMRN

Swedbank AB boosted its position in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) by 70.6% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 796,737 shares of the biotechnology company’s stock after purchasing an additional 329,794 shares during the period. Swedbank AB’s holdings in BioMarin Pharmaceutical were worth $47,350,000 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. Activest Wealth Management bought a new position in BioMarin Pharmaceutical during the 4th quarter worth about $26,000. Smartleaf Asset Management LLC increased its holdings in BioMarin Pharmaceutical by 92.5% during the 3rd quarter. Smartleaf Asset Management LLC now owns 749 shares of the biotechnology company’s stock worth $40,000 after purchasing an additional 360 shares in the last quarter. Caitong International Asset Management Co. Ltd bought a new position in BioMarin Pharmaceutical during the 3rd quarter worth about $40,000. Parallel Advisors LLC increased its holdings in BioMarin Pharmaceutical by 62.2% during the 3rd quarter. Parallel Advisors LLC now owns 769 shares of the biotechnology company’s stock worth $42,000 after purchasing an additional 295 shares in the last quarter. Finally, V Square Quantitative Management LLC bought a new position in BioMarin Pharmaceutical during the 4th quarter worth about $45,000. Institutional investors own 98.71% of the company’s stock.

Insider Transactions at BioMarin Pharmaceutical

In other news, EVP Charles Greg Guyer sold 16,486 shares of the stock in a transaction dated Wednesday, March 11th. The shares were sold at an average price of $60.46, for a total transaction of $996,743.56. Following the completion of the transaction, the executive vice president directly owned 79,953 shares in the company, valued at $4,833,958.38. This represents a 17.09% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, EVP Gregory R. Friberg sold 6,326 shares of the stock in a transaction dated Thursday, February 26th. The stock was sold at an average price of $60.38, for a total transaction of $381,963.88. Following the transaction, the executive vice president owned 37,578 shares of the company’s stock, valued at approximately $2,268,959.64. This represents a 14.41% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders have sold 26,093 shares of company stock valued at $1,555,389. Company insiders own 0.85% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have issued reports on BMRN shares. Citigroup started coverage on BioMarin Pharmaceutical in a report on Tuesday, May 19th. They set a “buy” rating and a $75.00 target price for the company. Morgan Stanley lowered their target price on BioMarin Pharmaceutical from $120.00 to $119.00 and set an “overweight” rating for the company in a report on Tuesday, May 5th. Sanford C. Bernstein lowered their target price on BioMarin Pharmaceutical from $94.00 to $82.00 and set an “outperform” rating for the company in a report on Tuesday, May 5th. Guggenheim lowered their target price on BioMarin Pharmaceutical from $106.00 to $86.00 and set a “buy” rating for the company in a report on Wednesday, February 25th. Finally, Oppenheimer reduced their price objective on shares of BioMarin Pharmaceutical from $98.00 to $95.00 and set an “outperform” rating for the company in a research note on Tuesday, February 24th. Two equities research analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating, six have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $88.67.

Key Headlines Impacting BioMarin Pharmaceutical

Here are the key news stories impacting BioMarin Pharmaceutical this week:

• Positive Sentiment: BioMarin said Voxzogo met its main goal in a late-stage hypochondroplasia study, supporting plans to file with the FDA in 2026 and boosting investor optimism about another potential growth driver. Article Title
• Positive Sentiment: Analyst commentary remained constructive overall, with Canaccord Genuity cutting its price target to $111 from $116 but reiterating a buy rating, implying substantial upside from current levels. Article Title
• Neutral Sentiment: Several press items from The Globe and Mail and TipRanks highlighted additional analyst coverage on BMRN, but they did not add a clear new operating catalyst beyond general sentiment and valuation commentary. Article Title
• Neutral Sentiment: BioMarin’s Phase 3 ENERGY 3 trial of BMN 401 met one co-primary endpoint but missed the other, making the readout mixed rather than clearly successful. Article Title
• Negative Sentiment: The mixed BMN 401 results triggered a notable selloff, with investors reacting to uncertainty around the drug’s commercial prospects and the likelihood of a clean regulatory path. Article Title

BioMarin Pharmaceutical Stock Performance

BioMarin Pharmaceutical stock opened at $54.09 on Monday. The firm has a 50-day moving average of $54.56 and a 200-day moving average of $56.27. BioMarin Pharmaceutical Inc. has a one year low of $49.26 and a one year high of $66.28. The company has a debt-to-equity ratio of 0.23, a current ratio of 5.81 and a quick ratio of 4.20. The company has a market cap of $10.45 billion, a price-to-earnings ratio of 39.48, a P/E/G ratio of 0.41 and a beta of 0.23.

BioMarin Pharmaceutical Company Profile

BioMarin Pharmaceutical Inc is a biopharmaceutical company specializing in the development and commercialization of therapies for rare genetic and metabolic diseases. The company focuses on addressing unmet medical needs by leveraging enzyme replacement therapy, small molecule pharmacological chaperones and gene therapy technologies. Headquartered in Novato, California, BioMarin operates research and development facilities in the United States and Europe.

The company’s commercial portfolio includes several approved therapies targeting inherited disorders.